PDCD1 and nasopharyngeal carcinoma: Among the total, three phase 3 RCTs that investigated a PD-1 inhibitor plus chemotherapy versus chemotherapy as first-line therapy for recurrent or metastatic NPC were identified: JUPITER-02 (10), RATIONALE-309 (11), and CAPTAIN-1st (12) [Table 1]).